KIT-exon-11 mutations in GISTs correlate with higher partial response rates and improved surgical outcomes with neoadjuvant Gleevec. Non-KIT exon 11 mutations and wild-type KIT/PDGFRA GISTs show less ...
Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...
When exposed to antibiotics, approximately one out of every 10 8 -10 9 bacteria develops resistance due to spontaneous ...
Blueprint Medicines' strong pipeline and Ayvakit growth make it promising. Read why BPMC stock is rated "Hold" due to high ...
Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced four preclinical poster presentations at ...
A Saint Louis University student is making a significant impact by organizing a blood stem cell donor registration drive on ...
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback